New Delhi: The Indian Narcotics Authority Authority Panel has recommended authorizing emergency use to Zydus Cadila from the Covid-19 vaccine Zycov-D vaccine, the source said.
The Subject Expert Committee (SEC) in Covid-19 Standard Control Organizational Center (CDSCO) negotiates on the application provided by Zydus Cadila on Thursday and recommends providing authorization of emergency use to the three-dose Koronavirus vaccine.
Recommendations have been sent to the drug controller General India (DCGI) for final approval.
Major Pharma based in Ahmedabad on July 1 was applied to authorize emergency use (EUA) with DCGI for vaccines.
The company said it had conducted the biggest clinical trial for vaccines in India in more than 50 centers so far.
If approved, Zycov-D will be the first DNA vaccine in the world against Coronavirus novel infection, developed by Indian companies and becomes the sixth vaccine that has been approved for use in this country after the Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia Sputnik V and Moderno and Moderno Johnson and Johnson made in the US.
Zycov-D DNA-based plasmid must be given intradermal using a needle-free injector.
Sharvil Patel, Managing Director, Cadila Healthcare said that the vaccine, when approved, would help not only adults but also adolescents in the age group 12 to 18 years.
Government panel recommends authorization of emergency use to Covid 3-dose vaccine Zydus Cadila
